Walvax Biotechnology approves key resolutions at 2024 AGM

Walvax Biotechnology held its 2024 Annual General Meeting on May 8, 2025, where shareholders approved several significant resolutions. Key agenda items included the approval of the 2024 Annual Report and its summary, the 2024 Board of Directors' work report, and the 2024 Supervisory Board's work report. Shareholders also approved the audited financial report for 2024, the financial budget for 2025, and the proposed profit distribution plan for 2024. The company also received approval for the revisions to its compensation management system. All resolutions passed with over 95% of the votes in favor. The meeting was conducted through a combination of on-site participation and online voting, with a total of 884 shareholders or their representatives, holding 172,192,834 shares, attending. Legal counsel from Beijing JingTian & GongCheng (Shenzhen) Attorneys at Law confirmed the meeting's compliance with relevant laws and regulations.